3rd Annual Personalized Cancer Vaccine Summit 2026

 

The personalized cancer vaccine field has reached a defining milestone. With Moderna and Merck reporting positive initial Phase 3 data for intismeran autogene in combination with Keytruda, the first regulatory approval of a personalized neoantigen cancer vaccine is now firmly within sight, accelerating momentum across the entire industry.

Yet significant challenges remain. As innovation accelerates, organizations must overcome key challenges spanning development, manufacturing, delivery, and market access.

The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, Transgene, and more, to share data-driven insights, benchmark strategies and forge long-term partnerships for driving personalized cancer vaccines closer to approval.

 

More Info

---

---